PF-00489791 + verapamil

PF-00489791 + verapamil is an investigational **combination therapy** for hypertension and potentially other cardiovascular or renal disorders. PF-00489791 is a novel, long-acting, selective **phosphodiesterase 5 (PDE5) inhibitor** under development primarily for blood pressure lowering and renal benefits[2][4][8][10]. **Verapamil** is a **phenylalkylamine calcium channel blocker** approved for hypertension, angina, and certain cardiac arrhythmias[1]. This combination may provide additive or synergistic antihypertensive effects by targeting vascular smooth muscle relaxation through two different mechanisms: increased cGMP (via PDE5 inhibition) and reduced calcium influx (via L-type calcium channel inhibition). PF-00489791 has been investigated in Phase 2 trials for hypertension and diabetic nephropathy[2][4], while verapamil is widely used for cardiovascular conditions. No unique brand or trade name for their combination is reported.